Scott A Holmes insider trades: Keryx Biopharmaceuticals (KERX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
23 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 15, 2018 | KERX | ↓ Sell | 1,155 | $2.77 | $3K | Direct | Nov 16, 2018 (1d) |
| Oct 29, 2018 | KERX | ↓ Sell | 1,254 | $3.07 | $4K | Direct | Oct 30, 2018 (1d) |
| Aug 15, 2018 | KERX | ↓ Sell | 1,185 | $3.04 | $4K | Direct | Aug 16, 2018 (1d) |
| Jul 30, 2018 | KERX | ↓ Sell | 2,354 | $3.86 | $9K | Direct | Jul 31, 2018 (1d) |
| May 15, 2018 | KERX | ↓ Sell | 1,158 | $5.69 | $7K | Direct | May 16, 2018 (1d) |
| Apr 30, 2018 | KERX | ↓ Sell | 2,407 | $4.67 | $11K | Direct | May 1, 2018 (1d) |
| Feb 15, 2018 | KERX | ↓ Sell | 5,651 | $4.81 | $27K | Direct | Feb 16, 2018 (1d) |
| Jan 29, 2018 | KERX | ↓ Sell | 2,830 | $4.81 | $14K | Direct | Jan 31, 2018 (2d) |
| Oct 30, 2017 | KERX | ↓ Sell | 2,582 | $6.03 | $16K | Direct | Oct 31, 2017 (1d) |
| Jul 31, 2017 | KERX | ↓ Sell | 1,445 | $7.14 | $10K | Direct | Aug 1, 2017 (1d) |
| Jul 28, 2017 | KERX | ↓ Sell | 1,236 | $6.96 | $9K | Direct | Jul 31, 2017 (3d) |
| May 1, 2017 | KERX | ↓ Sell | 1,441 | $5.97 | $9K | Direct | May 3, 2017 (2d) |
| Apr 28, 2017 | KERX | ↓ Sell | 1,219 | $5.89 | $7K | Direct | May 1, 2017 (3d) |
| Jan 30, 2017 | KERX | ↓ Sell | 8,447 | $4.65 | $39K | Direct | Jan 31, 2017 (1d) |
| Oct 28, 2016 | KERX | ↓ Sell | 1,237 | $4.44 | $5K | Direct | Oct 31, 2016 (3d) |
| Jul 29, 2016 | KERX | ↓ Sell | 4,935 | $7.36 | $36K | Direct | Aug 2, 2016 (4d) |
| Nov 4, 2015 | KERX | ↑ Buy | 5,000 | $5.33 | $27K | Direct | Nov 5, 2015 (1d) |
| Aug 21, 2015 | KERX | ↑ Buy | 5,000 | $5.72 | $29K | Direct | Aug 24, 2015 (3d) |
| Jul 31, 2015 | KERX | ↓ Sell | 2,758 | $7.87 | $22K | Direct | Aug 3, 2015 (3d) |
| Jun 15, 2015 | AMAG | ↓ Sell | 7,580 | $66.63 | $505K | Direct | Jun 17, 2015 (2d) |
| Jun 3, 2015 | AMAG | ↓ Sell | 22,516 | $68.88 | $1.6M | Direct | Jun 5, 2015 (2d) |
| Dec 5, 2012 | AMAG | ↓ Sell | 2,500 | $14.79 | $37K | Direct | Dec 6, 2012 (1d) |
| Sep 12, 2012 | AMAG | ↓ Sell | 750 | $15.54 | $12K | Direct | Sep 13, 2012 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Scott A Holmes's insider trades
Scott A Holmes is Chief Financial Officer at Keryx Biopharmaceuticals (KERX). Since Sep 12, 2012, Scott has reported 2 open-market purchases worth $55K and 21 sales worth $2.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), shares withheld for taxes (3 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KERX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.